Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
140
-
Total 13F shares, excl. options
-
28.3M
-
Shares change
-
-361K
-
Total reported value, excl. options
-
$599M
-
Value change
-
-$18.9M
-
Put/Call ratio
-
2.31
-
Number of buys
-
58
-
Number of sells
-
-74
-
Price
-
$21.15
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2021
189 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2021.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 140 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.3M shares
of 207M outstanding shares and own 13.66% of the company stock.
Largest 10 shareholders include Bellevue Group AG (4.52M shares), WASATCH ADVISORS INC (3.77M shares), Meditor Group Ltd (2.82M shares), VANGUARD GROUP INC (2.3M shares), STATE STREET CORP (2.25M shares), BlackRock Inc. (2.09M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.71M shares), MARSHALL WACE, LLP (1.17M shares), Rhenman & Partners Asset Management AB (572K shares), and BOXER CAPITAL, LLC (500K shares).
This table shows the top 140 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.